KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Moderna (MRNA) Change in Account Payables (2018 - 2025)

Historic Change in Account Payables for Moderna (MRNA) over the last 8 years, with Q3 2025 value amounting to $89.0 million.

  • Moderna's Change in Account Payables fell 729.17% to $89.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$80.0 million, marking a year-over-year increase of 243.9%. This contributed to the annual value of -$69.0 million for FY2024, which is 63076.92% down from last year.
  • As of Q3 2025, Moderna's Change in Account Payables stood at $89.0 million, which was down 729.17% from -$47.0 million recorded in Q2 2025.
  • Moderna's Change in Account Payables' 5-year high stood at $179.0 million during Q3 2023, with a 5-year trough of -$303.0 million in Q1 2024.
  • Moreover, its 5-year median value for Change in Account Payables was $21.0 million (2023), whereas its average is $14.4 million.
  • Data for Moderna's Change in Account Payables shows a peak YoY increase of 900000.0% (in 2021) and a maximum YoY decrease of 100000.0% (in 2021) over the last 5 years.
  • Quarter analysis of 5 years shows Moderna's Change in Account Payables stood at $178.0 million in 2021, then dropped by 15.17% to $151.0 million in 2022, then tumbled by 86.09% to $21.0 million in 2023, then surged by 61.9% to $34.0 million in 2024, then soared by 161.76% to $89.0 million in 2025.
  • Its last three reported values are $89.0 million in Q3 2025, -$47.0 million for Q2 2025, and -$156.0 million during Q1 2025.